Circulating plasma cells predict the outcome of relapsed or refractory multiple myeloma

Abstract Pretreatment detection of peripheral blood malignant circulating plasma cells (CPCs) has been shown to be of negative prognostic value in multiple myeloma (MM). We hypothesized that the assessment of CPC kinetics in response to one therapy cycle using six-color flow cytometry could be helpf...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia & lymphoma 2012-04, Vol.53 (4), p.641-647
Main Authors: Peceliunas, Valdas, Janiulioniene, Ausra, Matuzeviciene, Reda, Zvirblis, Tadas, Griskevicius, Laimonas
Format: Article
Language:English
Subjects:
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Boronic Acids - administration & dosage
Boronic Acids - therapeutic use
Bortezomib
circulating plasma cells
Dexamethasone - administration & dosage
Disease Progression
Doxorubicin - administration & dosage
Drug Resistance, Neoplasm
flow cytometry
Hematopoietic Stem Cell Transplantation
Humans
Middle Aged
Multiple Myeloma - blood
Multiple Myeloma - pathology
Multiple Myeloma - therapy
Multivariate Analysis
Myeloma
Neoplastic Cells, Circulating - drug effects
Neoplastic Cells, Circulating - pathology
Plasma Cells - drug effects
Plasma Cells - pathology
Prognosis
Prospective Studies
Pyrazines - administration & dosage
Pyrazines - therapeutic use
Recurrence
Survival Analysis
Time Factors
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Pretreatment detection of peripheral blood malignant circulating plasma cells (CPCs) has been shown to be of negative prognostic value in multiple myeloma (MM). We hypothesized that the assessment of CPC kinetics in response to one therapy cycle using six-color flow cytometry could be helpful in the early detection of MM refractoriness to treatment. Forty-two patients with refractory or relapsed (RR) MM were enrolled. Median time to tumor progression (TTP) of 51 days and median overall survival (OS) of 308 days was shortest in patients whose CPCs with aberrant phentoype (aCPCs) did not decrease after one therapy cycle compared to patients with decreasing (median TTP 258 days and OS 856 days) or undetectable (median TTP 581 days and OS 1006 days) aCPCs (p < 0.001 and p = 0.007 for TTP and OS, respectively). Non-reduction of aCPCs in patients with RR MM after the first cycle of therapy may be useful in early identification of patients resistant to a given therapy.
ISSN:1042-8194
1029-2403
DOI:10.3109/10428194.2011.627481